+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Chemotherapy of advanced non-small-cell lung cancer: a comparison of three active regimens. A randomized trial of the Italian Oncology Group for Clinical Research (G.O.I.R.C.)



Chemotherapy of advanced non-small-cell lung cancer: a comparison of three active regimens. A randomized trial of the Italian Oncology Group for Clinical Research (G.O.I.R.C.)



Annals of Oncology 6(4): 347-353



Cisplatin-based chemotherapy is generally considered the most active treatment for advanced non-small-cell lung cancer. The combination of cisplatin and etoposide had for some time been the standard treatment at our center. Of the other active regimens, cisplatin in combination with mitomycin-C, vindesine or ifosfamide (MVP or MIC) showed the highest response rates. We decided to perform a comparative trial of the three 'best' regimens in order to define a possible standard regimen in advanced NSCLC. From May 1989 to April 1992, 393 consecutive, previously untreated NSCLC patients, stages IIIB and IV, were randomized to receive either cisplatin (120 mg/sqm day 1) + etoposide (100 mg/sqm days 1-3) every 3 weeks (PE) or cisplatin (120 mg/sqm every 4 weeks) + mitomycin-C (8 mg/sqm days 1-29-71) + vindesine (3 mg/sqm days 1-8-15-22) (MVP) or cisplatin (120 mg/sqm day 1) + mitomycin-C (6 mg/sqm day 1) + ifosfamide (3 mg/sqm day 2) every 3 weeks (MIC). Of these, 382 were evaluable for survival and 360 for response. Response rates were statistically higher for both MIC (40%) and MVP (36%) than for the PE arm (23%). Survival estimates analyzed by the log-rank test showed a significant benefit (p < 0.04) for patients treated with three-drug regimens (MVP; MIC) as compared to those in the PE arm. The main toxicity was myelosuppression; thrombocytopenia WHO grade 3-4 was worse in the MIC arm; nephrotoxicity grade 3-4 was also more frequent in the MIC arm. A three-drug cisplatin-based regimen (MVP; MIC) should be considered as reference treatment in NSCLC.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 042522427

Download citation: RISBibTeXText

PMID: 7619749

DOI: 10.1016/0169-5002(95)90687-8


Related references

Superiority of three-drug combination chemotherapy versus cisplatin-etoposide in advanced non-small cell lung cancer: a randomized trial by the Italian Oncology Group for Clinical Research. Lung Cancer 12(Suppl. 1): S125-S132, 1995

Randomized phase III comparison of three doxorubicin-based chemotherapy regimens in advanced non-small cell lung cancer: a Southeastern Cancer Study Group trial. Journal of Clinical Oncology 2(5): 391-395, 1984

A comparison of continuation versus late intensification followed by discontinuation of chemotherapy in advanced breast cancer. A prospective randomized trial of the Italian Oncology Group for Clinical Research (G.O.I.R.C.). Annals of Oncology 1(1): 36-44, 1990

Advanced non-small cell lung cancer chemotherapy: A randomized trial of two active regimens (MVP and PE). Cancer Letters 119(2): 241-247, 1997

Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. Journal of Clinical Oncology 18(12): 2354-2362, 2000

Platinum and etoposide pe vs camp in advanced non small cell lung cancer nsclc a prospective randomized study of the italian oncology group for clinical research goirc preliminary data. Cancer Immunology Immunotherapy 23(Suppl.): A43, 1986

Fluorouracil, doxorubicin, and mitomycin combination versus PELF chemotherapy in advanced gastric cancer: a prospective randomized trial of the Italian Oncology Group for Clinical Research. Journal of Clinical Oncology 12(12): 2687-2693, 1994

Platinum p and etoposide e as a third line chemotherapy regimen in advanced breast cancer abc a randomized trial of the italian oncology group for clinical research goirc preliminary report. Cancer Immunology Immunotherapy 23(Suppl.): A9, 1986

Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group--EORTC 08975. Journal of Clinical Oncology 21(21): 3909-3917, 2003

Bolus versus 5-day continuous infusion of cisplatin with mitomycin and vindesine in the treatment of advanced non-small cell lung cancer (NSCLC): a phase III prospective randomised trial of the Italian Oncology Group for Clinical Research (GOIRC). European Journal of Cancer 34(12): 1974-1976, 1998

Randomized comparison of 5 fluorouracil alone or combined with carmustine doxorubicin and mitomycin in the treatment of advanced gastric cancer a phase iii trial of the italian clinical research oncology group. Cancer Treatment Reports 70(4): 481-486, 1986

Chemotherapy of advanced non-small-cell lung cancer: a randomized trial of three cis-platin-based chemotherapy regimens. American Journal of Clinical Oncology 12(4): 345-349, 1989

Randomized comparison of 5-FU alone or combined with carmustine, doxorubicin, and mitomycin (BAFMi) in the treatment of advanced gastric cancer: a phase III trial of the Italian Clinical Research Oncology Group (GOIRC). Cancer Treatment Reports 70(4): 481-485, 1986

Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01. Journal of Clinical Oncology 23(10): 2145-2154, 2005

Randomized Trial of Amifostine in Locally Advanced Non-Small-Cell Lung Cancer Patients Receiving Chemotherapy and Hyperfractionated Radiation: Radiation Therapy Oncology Group Trial 98-01. Yearbook of Oncology 2006: 207-208, 2006